RCT-2100 is under development for the treatment of cystic fibrosis (CF). The therapeutic candidate is an mRNA, encoding cystic fibrosis transmembrane conductance regulator (CFTR). It is administered ...

A connection between lung health and kidney function in adults with cystic fibrosis (CF), identifying early urinary markers ...

Galicaftor is under clinical development by Sionna Therapeutics and currently in Phase II for Cystic Fibrosis.

Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...

Cystic fibrosis is a genetic disorder that affects various organs, including the lungs and digestive system. Medications are important for managing symptoms, but there is currently no cure for the ...

Ed Arce, an analyst from H.C. Wainwright, maintained the Buy rating on Arcturus Therapeutics (ARCT – Research Report). The associated price ...

(MENAFN- EIN Presswire) Numerous companies, such as Vertex Pharmaceuticals, Eloxx Pharmaceuticals, and others, are actively developing treatments in the Cystic Fibrosis market. LAS VEGAS ...

Biomarker staging of liver fibrosis in hepatitis C was cost effective, but so was initiating treatment without testing.